Vion porfiromycin for head and neck cancer Phase III expanded trial planned -- IPO.
VION PORFIROMYCIN HEAD AND NECK CANCER EXPANDED PHASE III TRIAL planned with proceeds from the company's August 1995 initial public offering and a private placement of Class A preferred stock in May, Vion Pharmaceuticals states in a July 3 registration for resale by security holders. A Phase III trial is ongoing at Yale University, and the company is designing an expanded trial that will include additional sites. Porfiromycin has been designated an orphan drug by FDA.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth